Ulcerative colitis and Crohn's disease are inflammatory bowel diseases with a chronic relapsing course. Management of both conditions is far from being fully satisfactory. For this reason in the last decade a large number of biological therapies, targeting cytokines involved in intestinal inflammation, has been developed with various results in terms of efficacy, safety and costs. Activated granulocytes and monocytes represent the major sources of pro-inflammatory cytokines in the intestinal mucosa, playing a pivotal role in inducing and maintaining intestinal inflammation. Leukocytapheresis using an adsorptive carrier-based system (Adacolumn (R)) or a removal filter column (Cellsorba (R)) has been proposed as a feasible, safe and effective therapy for ulcerative colitis and Crohn's disease. The objective of this paper is to provide an overview on the current knowledge about mechanisms of action, available clinical data and the possible future perspectives for the use of Adacolumn and Cellsorba in the management of inflammatory bowel diseases. Copyright (C) 2008 S. Karger AG, Basel.
|Titolo:||Cytapheresis in inflammatory bowel diseases: Current evidence and perspectives|
|Data di pubblicazione:||2008|
|Appare nelle tipologie:||1.1 Articolo in rivista|
File in questo prodotto:
|Cytapheresis in Inflammatory Bowel Diseases Current Evidence and Perspectives.pdf||Versione Editoriale (PDF)||Copyright dell'editore||Administrator Richiedi una copia|